🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2-positive Advanced Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer NCT06123988NA3 sites📍 Phoenix📍 Miami📍 Boston University of Miami · Tests: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site📍 Zhejiang Zhejiang Cancer Hospital · Tests: Antitumor treatment plan FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy ARX788 in HER2-positive Metastatic Breast Cancer Patients NCT06663748Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: ARX788 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185Phase 41 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Pyrotinib, Trastuzumab, Taxanes, Capecitabine Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer NCT07047365Phase 375 sites📍 Bengbu📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2930+ chemotherapy, Trastuzumab+ chemotherapy SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569n/a1 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Trastuzumab deruxtecan (DS-8201a) Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure NCT07708194Phase 1, Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: entinostat, Pyrotinib, endocrine therapy A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites📍 Huntsville📍 Gilbert📍 San Francisco Hoffmann-La Roche · Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site📍 La Jolla University of California, San Diego · Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physicia… A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer NCT06856200NA1 site📍 Shanghai Fudan University · Tests: Sirolimus (albumin - bound), Palbociclib, Fulvestrant ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management NCT05362760Phase 454 sites📍 Aalen📍 Amberg📍 Aschaffenburg Prof. Wolfgang Janni · Tests: Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822Phase 340 sites📍 Largo📍 Fort Wayne📍 Omaha AstraZeneca · Tests: Dato-DXd Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors NCT06950086Phase 1, Phase 22 sites📍 Shanghai📍 Shanghai TYK Medicines, Inc · Tests: TYK-00540 Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer NCT04481932Phase 21 site📍 Beijing Peking University · Tests: Trastuzumab combined with Pyrotinib and chemotherapy Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites📍 St Louis📍 East Providence📍 Nashville AstraZeneca · Tests: Camizestrant, Atirmociclib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy